플랫폼과 전략

논문 &학회발표

Home플랫폼과 전략논문 &학회발표

학회발표 검색 폼 search
게시물 목록(NO,과제,학회,발표제목,발표자료)
NO 과제 학회 발표제목 발표자료
18 Neuroscience CVB2023 Grabody B, an IGF1 receptor based shuttle, mediates efficient delivery of biologics across the blood brain barrier PDF 아이콘
17 ABL001 PEGS 2017 Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 PDF 아이콘
16 ABL001 ASCO 2019 Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer PDF 아이콘
15 ABL001 PEPTALK 2020 Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors PDF 아이콘
14 ABL105 ESMO2021 A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation PDF 아이콘
13 4-1BB Platform AACR 2020 B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity PDF 아이콘
12 4-1BB Platform AACR 2021 A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format PDF 아이콘
11 ABL503 SITC2021 ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment PDF 아이콘
10 ABL503 PEGS 2019 The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation PDF 아이콘
9 ABL111 SITC2021 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies PDF 아이콘

12다음페이지로마지막페이지로

ABL Bio

메뉴닫기